HLA-DR and HLA-DP Restricted Epitopes from Human Cytomegalovirus Glycoprotein B Recognized by CD4+ T-Cell Clones from Chronically Infected Individuals

详细信息    查看全文

• 作者：Claire Ventura (1)
  Hélène Bisceglia (2)
  Yves Girerd-Chambaz (2)
  Nicolas Burdin (2)
  Pascal Chaux (2) (3)
  
• 关键词：Cytomegalovirus ; glycoprotein B ; CD4+ T cells ; HLA ; class II
• 刊名：Journal of Clinical Immunology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：32
• 期：6
• 页码：1305-1316
• 全文大小：793KB
• 参考文献：1. Revello MG, Lilleri D, Zavattoni M, Furione M, Genini E, Comolli G, et al. Lymphoproliferative response in primary human cytomegalovirus (HCMV) infection is delayed in HCMV transmitter mothers. J Infect Dis. 2006;193(2):269-6. CrossRef
  2. Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis. 2003;188(12):1868-4. CrossRef
  3. Lilleri D, Zelini P, Fornara C, Comolli G, Revello MG, Gerna G. Human cytomegalovirus-specific CD4(+) and CD8(+) T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clin Immunol 2009 Mar 4.
  4. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003;101(7):2686-2. CrossRef
  5. Schleiss MR. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361-2. CrossRef
  6. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect. 2007;13(10):953-3. CrossRef
  7. Chen FE, Aubert G, Travers P, Dodi IA, Madrigal JA. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy. 2002;4(1):41-. CrossRef
  8. Khan N, Cobbold M, Keenan R, Moss PA. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp 65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis. 2002;185(8):1025-4. CrossRef
  9. Moss P, Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol. 2004;65(5):456-4. CrossRef
  10. Schalich J, Vytvytska O, Zauner W, Fischer MB, Buschle M, Aichinger G, et al. Analysis of the human cytomegalovirus pp 65-directed T-cell response in healthy HLA-A2-positive individuals. Biol Chem. 2008;389(5):551-. CrossRef
  11. Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp 65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant. 2007;7(8):1997-005. CrossRef
  12. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 1990;64(3):1079-5.
  13. Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc. 1991;23(3 Suppl 3):90-.
  14. Potzsch S, Spindler N, Wiegers AK, Fisch T, Rucker P, Sticht H, et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 2011;7(8):e1002172. CrossRef
  15. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191-. CrossRef
  16. Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis. 2011;203(11):1534-1. CrossRef
  17. Gamadia LE, Rentenaar RJ, van Lier RA, Ten Berge IJ. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol. 2004;65(5):486-2. CrossRef
  18. Harcourt GC, Scriba TJ, Semmo N, Bounds S, Taylor E, Klenerman P. Identification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol. 2006;146(2):203-0. CrossRef
  19. Nepom GT. MHC class II tetramers. J Immunol. 2012;188(6):2477-2. CrossRef
  20. Wulf M, Hoehn P, Trinder P. Identification and validation of T-cell epitopes using the IFN-gamma ELISPOT assay. Methods Mol Biol. 2009;524:439-6. CrossRef
  21. De Rosa SC. Vaccine applications of flow cytometry. Methods 2012 Jan 10.
  22. Kaelin Jr WG, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell. 1992;70(2):351-4. CrossRef
  23. Bunce M, O’Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995;46(5):355-7. CrossRef
  24. Elkington R, Shoukry NH, Walker S, Crough T, Fazou C, Kaur A, et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol. 2004;34(11):3216-6. CrossRef
  25. Crompton L, Khan N, Khanna R, Nayak L, Moss PA. CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood. 2008;111(4):2053-1. CrossRef
  26. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol. 2002;169(12):6928-4.
  27. Yang J, Huston L, Berger D, Danke NA, Liu AW, Disis ML, et al. Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells. J Clin Immunol. 2005;25(5):428-6. CrossRef
  28. Hegde NR, Dunn C, Lewinsohn DM, Jarvis MA, Nelson JA, Johnson DC. Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med. 2005;202(8):1109-9. CrossRef
  29. Dunn HS, Haney DJ, Ghanekar SA, Stepick-Biek P, Lewis DB, Maecker HT. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis. 2002;186(1):15-2. CrossRef
  30. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673-5. CrossRef
  31. Pourgheysari B, Khan N, Best D, Bruton R, Nayak L, Moss PA. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol. 2007;81(14):7759-5. CrossRef
  32. Provenzano M, Sais G, Bracci L, Egli A, Anselmi M, Viehl CT, et al. A HCMV pp 65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities. J Cell Mol Med. 2009;13(8B):2131-7. CrossRef
  33. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, et al. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood. 2003;101(3):1038-4. CrossRef
  34. van de Corput L, Chaux P, van der Meijden ED, De Plaen E, Frederik Falkenburg JH, van der Bruggen P. A novel approach to identify antigens recognized by CD4 T cells using complement-opsonized bacteria expressing a cDNA library. Leukemia. 2005;19(2):279-5. CrossRef
  35. Schub A, Schuster IG, Hammerschmidt W, Moosmann A. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol. 2009;183(10):6819-0. CrossRef
  
• 作者单位：Claire Ventura (1)
  Hélène Bisceglia (2)
  Yves Girerd-Chambaz (2)
  Nicolas Burdin (2)
  Pascal Chaux (2) (3)
  
  1. Sanofi Pasteur Biologics Co, 38 Sidney St, Cambridge, MA, 02139, USA
  2. Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280, Marcy l’Etoile, France
  3. Discovery Department, Sanofi Pasteur, 1541 Avenue Marcel Mérieux, 69280, Marcy l’Etoile, France
  
• ISSN：1573-2592

文摘

Purpose Helper CD4+ T cells presumably play a major role in controlling cytomegalovirus (CMV) by providing help to specific B and CD8+ cytotoxic T cells, as well as through cytotoxicity-mediated mechanisms. Since CMV glycoprotein B (gB) is a major candidate for a subunit vaccine against CMV, we searched for gB-epitopes presented by human leukocyte antigen (HLA)-class II molecules. Methods Dendritic cells obtained from CMV-seropositive donors were loaded with a recombinant gB and co-cultured with autologous CD4+ T cells. Microcultures that specifically recognized gB were cloned by limiting dilution using autologous Epstein-Barr virus (EBV)-immortalized B cells pulsed with gB as antigen-presenting cells. To pinpoint precisely the region encoding the natural epitope recognized by a given CD4+ clone, we assessed the recognition of recombinant Escherichia coli expressing gB-overlapping polypeptides after their processing by autologous EBV-B cells. Results We isolated several gB-specific CD4+ T-cell clones directed against peptides gB190-204, gB396-410, gB22-36 and gB598-617 presented by HLA-DR7, HLA-DP10 and HLA-DP2. While their precise role in controlling CMV infection remains to be established, gB-specific CD4+ T cells are likely to act by directly targeting infected HLA-class II cells in vivo, as suggested by their recognition of EBV-B cells infected by the Towne CMV strain. Conclusions The characterization of such gB-epitopes presented by HLA-class II should help to understand the contribution of CD4+ T-cell responses to CMV and may be of importance both in designing a vaccine against CMV infection and in immunomonitoring of subjects immunized with recombinant gB or with vectors encoding gB.